IL1RL2 and Arthritis: However, treatment with an IL-36R-blocking antibody of TNF-transgenic mice, another experimental model of RA, resulted in no changes in symptoms or clinical onset, suggesting that the severity of experimental arthritis is independent of IL-36R signaling [38, 39].